ADHD Medication Selection Using Genotype-Based Phenotype Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Attention Deficit Hyperactivity Disorder (ADHD) lack a rational approach to selecting medications based on a patient's genetic predisposition, leading to ineffective treatments and potential adverse side effects.
Innovation Solution
A method involving genotyping a panel of genes associated with drug metabolism and neurotransmission, such as CYP2D6, COMT, SLC6A2, SLC6A3, and DRD4, to determine a patient's phenotype, which is then used to select and dose medications like methylphenidate, amphetamines, or atomoxetine, using an algorithm to optimize treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for treating ADHD are used without genetic testing, then treatment selection is simple and quick, but treatment efficacy is low and side effects occur due to lack of personalized approach
Solution Approach 1:
The patent applies preliminary action by conducting genetic testing before medication selection to identify patients at risk for adverse effects. The method determines genotype for CYP2D6 and other genes prior to treatment initiation, allowing clinicians to select medications that are likely to be effective and safe for each patient, thereby improving treatment efficacy while preventing adverse effects before they occur.
Solution Approach 2:
The patent applies parameter changes by using genetic information (genotype) to determine pharmacological parameters such as drug metabolism rate and receptor sensitivity. By analyzing variations in genes like CYP2D6, COMT, and neurotransmitter transporter genes, the method adjusts medication selection and dosing parameters to match individual patient characteristics, optimizing treatment outcomes.
2Reliability
If multiple medications are tried to find effective treatment, then treatment efficacy may improve, but time is lost and side effects increase from trial and error
Solution Approach 1:
The patent eliminates trial and error by performing genetic testing beforehand to identify the most suitable medication. The method determines a patient's metabolic phenotype and neurotransmitter profile prior to treatment, enabling immediate selection of an effective medication rather than attempting multiple drugs sequentially, thus saving time while maintaining high efficacy.
Solution Approach 2:
The patent incorporates feedback by using genetic test results to guide medication selection. The method analyzes genotype data from genes involved in drug metabolism and neurotransmission, processes this information through algorithms, and provides personalized treatment recommendations based on the patient's unique biological profile, ensuring the first medication chosen is likely to be effective.
3Object-affected harmful factors
If generic medication selection is used without considering genetics, then the process is simple, but adverse side effects occur due to not accounting for individual genetic variations
Solution Approach 1:
The patent prevents adverse effects by conducting genetic testing before medication initiation. The method determines genotype for CYP2D6 and other relevant genes prior to treatment, identifying patients at risk for adverse reactions and selecting alternative medications that are safer for their genetic profile, thereby preventing harm before it occurs.
Solution Approach 2:
The patent uses genetic information as an intermediary between the patient and medication selection. The method analyzes genetic data from genes like CYP2D6, COMT, and neurotransmitter transporter genes to create a personalized pharmacological profile that mediates the decision-making process, ensuring medication selection is based on individual biological characteristics rather than generic protocols.
4Measurement precision
If personalized medication selection based on genetics is implemented, then treatment precision improves, but cost and complexity of the system increase
Solution Approach 1:
The patent applies segmentation by dividing the treatment selection process into distinct components: genetic testing for specific genes (CYP2D6, COMT, neurotransmitter genes), bioinformatics analysis, and clinical decision support. This segmented approach makes the complex system more manageable and implementable by addressing each component separately while achieving high treatment precision through integration of these segments.
Data Source
AI summary
Methods for selecting a medication for a patient are described that include determining the patient's genotype for a panel of genes, identifying a phenotype associated with the genotype for each gene, and selecting the medication based on the phenotype.